

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1170231
<b>Application Number:</b>	10598338
<b>Confirmation Number:</b>	2755
<b>Title of Invention:</b>	LHR1 ACTIVATORS AS MEDICAMENTS
<b>First Named Inventor:</b>	Bryan James GOODWIN
<b>Customer Number:</b>	23347
<b>Filer:</b>	Michael M. Conger/Marjorie Pfeiffer
<b>Filer Authorized By:</b>	Michael M. Conger
<b>Attorney Docket Number:</b>	PR60742USw
<b>Receipt Date:</b>	24-AUG-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	14:50:50
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	PCT/US05/05754

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$1300
RAM confirmation Number	21
Deposit Account	071392
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	
Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages				
1	Documents submitted with 371 Applications	Transmittal_Letter.pdf	160145	no	3				
<b>Warnings:</b>									
<b>Information:</b>									
2	Oath or Declaration filed	Declaration.pdf	185235	no	6				
<b>Warnings:</b>									
<b>Information:</b>									
3	Power of Attorney (may include Associate POA)	Power_of_Attorney.pdf	78868	no	2				
<b>Warnings:</b>									
<b>Information:</b>									
4	Assignee showing of ownership per 37 CFR 3.73(b).	Statement_under_37CFR37 3b.pdf	103221	no	3				
<b>Warnings:</b>									
<b>Information:</b>									
5		Preliminary_Amendment.pdf	116266	yes	8				
	<b>Multipart Description</b>								
	<b>Doc Desc</b>		<b>Start</b>	<b>End</b>					
	Preliminary Amendment		1	2					
	Specification		3	3					
	Claims		4	6					
	Applicant Arguments/Remarks Made in an Amendment		7	7					
	Abstract		8	8					
<b>Warnings:</b>									
<b>Information:</b>									
6	Information Disclosure Statement (IDS) Filed	Information_Disclosure_Statement.pdf	234252	no	3				
<b>Warnings:</b>									
<b>Information:</b>									
This is not an USPTO supplied IDS fillable form									

7	Documents submitted with 371 Applications	International_Search_Report.pdf	201779	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	Documents submitted with 371 Applications	Written_Opinion.pdf	193645	no	8
<b>Warnings:</b>					
<b>Information:</b>					
9	Documents submitted with 371 Applications	Notification_Recording_of_Change.pdf	36114	no	1
<b>Warnings:</b>					
<b>Information:</b>					
10	Documents submitted with 371 Applications	PCT_Publication_Cover_Page.pdf	39404	no	1
<b>Warnings:</b>					
<b>Information:</b>					
11	Documents submitted with 371 Applications	PCT_Request.pdf	89127	no	5
<b>Warnings:</b>					
<b>Information:</b>					
12	Fee Worksheet (PTO-875)	fee-info.pdf	8509	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>					1446565
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b>New Applications Under 35 U.S.C. 111</b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b>National Stage of an International Application under 35 U.S.C. 371</b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					